TRIM65

Across TCGA pan-cancer cohorts, TRIM65 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TRIM65 data layer compared with 21 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher TRIM65 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TRIM65 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where TRIM65 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	III,IV	0.215	0.498	.002	34	view →
CCRCC	OS	Quartile	All	0.863	1.000	.020	8	view →
LUAD	OS	Median	II,III,IV	0.517	0.785	.028	4	view →
HNSC	OS	Median	All	0.994	0.942	.038	2	view →
LSCC	DFS	Median	II,III,IV	1.000	0.502	.038	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TRIM65–PDAC (DFS)

Open the PDAC breakdown →